Research and development for in-space production concepts of nanobioreactor models. This was awarded off of the NASA research announcement NNJ13ZBG001N. Note that "basic research" is not a…
Active Purchase Order Awarded Last action
- Contract number
- 80JSC025PA001
- Awardee
-
Aspera Biomedicines, Inc. UEI NYB9H3MV8C15
- Awarding agency
-
Johnson Space Center
National Aeronautics and Space Administration
- Obligated
- $6,450,000
Award facts
- Opportunity
-
- ISS NRA Mission Partnerships: CPF, OCO-3, SAGE III Special Notice · NNJ13ZBG001N · Posted Aug 11, 2025
- Contract value 50% obligated
- $12,984,612.60 Current and potential, with all options
- Completion date 60% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- La Jolla, CA 92037, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $3,210,000 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $1,080,000 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $720,000 | |
| Modification | $650,000 | |
| Funding Only Action | $790,000 |
About this award
NASA Johnson Space Center awarded a purchase order to Aspera Biomedicines, Inc. for $12,984,612.60 on December 5, 2024, to conduct research and development for in-space production concepts of nanobioreactor models. The order, issued under NASA Research Announcement NNJ13ZBG001N, carries a firm fixed price and extends through February 15, 2028. Work is performed in La Jolla, California. The statement of work expands the INSPA Phase 2 effort by adding five International Space Station investigations supporting continued tumor organoid research, protein crystallization, rebecsinib formulation development, and submission of a second FDA pre-investigational new drug application.
Description
Research and development for in-space production concepts of nanobioreactor models. This was awarded off of the NASA research announcement NNJ13ZBG001N. Note that "basic research" is not a selectable solicitation type for purchase orders in fpds.
Quick answers
Who was awarded contract 80JSC025PA001?
80JSC025PA001 was awarded to Aspera Biomedicines, Inc. by Johnson Space Center (National Aeronautics and Space Administration) on December 5, 2024.
How much is contract 80JSC025PA001 worth?
The government has obligated $6,450,000 on 80JSC025PA001. Its current value, with exercised options, is $12,984,613.
Was contract 80JSC025PA001 competed?
The extent of competition for 80JSC025PA001 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award